glp-1 obesity drugs pipeline Market Overview: Agonists and the Market | Blog GLP-1-based therapies for diabetes, obesity

When it is combined with other diabetes medications, particularly insulin and insulin secretagogues, hypoglycemia can occur

Obesity, primarily associated with the increased burden of non-communicable diseases (NCDs), has been linked to healthcare costs approximately 30% higher than those of individuals with normal body weight [9]

Zevay names two pharmacy partners - Southend Pharmacy and Boothwyn Pharmacy - that prepare and dispense compounded medication when a provider prescribes it

Another update recommends considering glucagonlike peptide1 [GLP1] receptor agonists for highrisk patients with CVD who have type 2 diabetes, which is in line with the findings of recently published clinical trials, including the LEADER (ClinicalTrials.gov identifier: NCT01179048) trials 2

In WT mice and in isolated atrial cardiomyocytes, liraglutide stimulates the production and secretion of atrial natriuretic peptide (ANP), and liraglutide fails to induce natriuresis and to lower BP in ANP KO mice [640]

M.CorkS